Eyenovia Business Development and Partners

We envision the Optejet® being utilized for additional applications. Reduction in systemic exposure and toxicity with Optejet’s microdosing, compared to a traditional eyedropper, could mean a better tolerability and safety profile than existing topical treatments. For therapies where adherence is vital to treatment success, the Optejet can assist with patient compliance.

We believe our technology platform improves the therapeutic profile of new and existing drug solutions. We believe the Optejet can improve the therapeutic profile of many new and existing drug products. The Optejet device has patent protection until 2041.

For Future Licensing Opportunities

Future Licensing Opportunities

If your product could benefit from any of the features that our technology makes possible, please contact us for an introductory discussion. Some of these features may include:

Improved ease-of-use, especially in populations where using eye drops may be difficult
Improved therapeutic index, maintaining efficacy while potentially reducing topical and systemic side effects
Improved tolerability, especially with formulations at very low or high pH
Preserved, minimally preserved, or non-preserved formulations
Improved compliance and adherence, with smart technology paired to smart phones for reminders and tracking usage

If you are interested in potential licensing opportunities, please complete the form below.

Date*
MM slash DD slash YYYY
Name*
First Last
Company*
Email*
Message*
Phone*